Diphenoxylate-Atropine en es it fr

Categorie

Diphenoxylate-Atropine Les marques, Diphenoxylate-Atropine Analogs

Diphenoxylate-Atropine Les marques melange

  • Lomotil (Atropine Sulfate + Diphenoxylate Hcl)
  • Diphenoxylate-Atropine Formule chimique

    C30H32N2O2

    Diphenoxylate-Atropine RX lien

    http://www.rxlist.com/cgi/generic3/diphenoxylate.htm

    Diphenoxylate-Atropine FDA fiche

    Diphenoxylate-Atropine msds (fiche de securite des materiaux)

    Diphenoxylate-Atropine MSDS

    Diphenoxylate-Atropine Synthese de reference

    Janssen, le brevet américain. 2,898,340 (1959)

    Diphenoxylate-Atropine Poids moleculaire

    452.587 g/mol

    Diphenoxylate-Atropine Point de fusion

    221 oC

    Diphenoxylate-Atropine H2O Solubilite

    0,8 mg / ml

    Diphenoxylate-Atropine Etat

    Solid

    Diphenoxylate-Atropine LogP

    7.385

    Diphenoxylate-Atropine Formes pharmaceutiques

    Solution orale; Tablet

    Diphenoxylate-Atropine Indication

    Pour la thérapie comme traitement d'appoint dans le traitement de la diarrhée

    Diphenoxylate-Atropine Pharmacologie

    Diphénoxylate, un anti-diarrhéique, est efficace comme thérapie adjuvante dans le traitement de la diarrhée. Diphénoxylate est rapidement et largement métabolisé chez l'homme par hydrolyse de l'ester de l'acide diphenoxylic (difenoxine), qui est biologiquement active et le principal métabolite dans le sang.

    Diphenoxylate-Atropine Absorption

    90%

    Diphenoxylate-Atropine Toxicite

    Coma, peau et muqueuses sèches, dilatation des pupilles des yeux, la température du corps extrêmement élevée, bouffées vasomotrices, mouvements du globe oculaire involontaire, inférieure à la normale du tonus musculaire, rétrécissement des pupilles, un pouls rapide, de l'agitation, la morosité, supprimé la respiration

    Diphenoxylate-Atropine Information pour les patients

    INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE RECOMMENDED DOSAGE AND TO KEEP DIPHEN-OXYLATE HCL AND ATROPINE SULFATE OUT OF THE REACH OF CHILDREN AND IN A CHILD-RESISTANT CONTAINER, INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.

    Diphenoxylate HCl and atropine sulfate may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operati ng dangerous machinery. Potentiation of the action of alcohol, barbiturates and tranquilizers with concomitant use of diphenoxylate HCl and atropine sulfate should be explained to the patient. The physician should also provide the patient with other information in this labeling, as appropriate.

    Diphenoxylate-Atropine Organismes affectes

    Les humains et autres mammifères